The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

OncoSec helps 57% of non-responders to immunotherpy become responders

Forums General Melanoma Community OncoSec helps 57% of non-responders to immunotherpy become responders

  • This topic is empty.
  • Post
    Anonymous
    Inactive

    Interesting findings: https://seekingalpha.com/article/4122712-oncosec-presses-forward-positive-melanoma-combo-study

     

    "The phase 2 results showed that the patients in the trial that took the combo therapy (ImmunoPulse IL-12 and Keytruda) achieved a 57% progression-free survival rate at 15 months. That is pretty impressive, especially when you consider the fact that these patients didn't respond at all with an anti-PD-1 alone. What's even better is the fact that 11 out of 11 or 100% of the patients had a duration of response. In addition, the median PFS has not yet been reached."

  • You must be logged in to reply to this topic.
About the MRF Patient Forum

The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

Popular Topics